Author:
Tentler John J.,Tan Aik Choon,Weekes Colin D.,Jimeno Antonio,Leong Stephen,Pitts Todd M.,Arcaroli John J.,Messersmith Wells A.,Eckhardt S. Gail
Publisher
Springer Science and Business Media LLC
Reference118 articles.
1. Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424–1431 (2001).
2. Daniel, V. C. et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69, 3364–3373 (2009).
3. Giovanella, B. C. et al. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science 246, 1046–1048 (1989).
4. Houghton, J. A., Maroda, S. J. Jr, Phillips, J. O. & Houghton, P. J. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res. 41, 144–149 (1981).
5. Houghton, J. A. & Taylor, D. M. Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br. J. Cancer 37, 213–223 (1978).